Parami, Ferlie R.
HRN: 21-47-98 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/25/2022
CO-AMOXICLAV 625MG (TAB)
06/25/2022
07/02/2022
ORAL
625mg/tab
BID
S/P NSVD With 1st Degree Perineal Laceration
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes